Navidea Biopharmaceuticals (NAVB) Stock Price Down 16.7%

Share on StockTwits

Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) shares fell 16.7% during trading on Monday . The company traded as low as $0.14 and last traded at $0.15. 1,608,335 shares changed hands during mid-day trading, an increase of 177% from the average session volume of 579,737 shares. The stock had previously closed at $0.18.

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) last announced its quarterly earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.02) EPS for the quarter. The firm had revenue of $0.12 million during the quarter.

In related news, major shareholder John K. Jr. Scott bought 357,143 shares of the stock in a transaction that occurred on Friday, March 22nd. The stock was acquired at an average cost of $0.14 per share, with a total value of $50,000.02. Following the transaction, the insider now directly owns 22,261,565 shares in the company, valued at $3,116,619.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

An institutional investor recently raised its position in Navidea Biopharmaceuticals stock. Virtu Financial LLC grew its holdings in shares of Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) by 94.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 186,972 shares of the biopharmaceutical company’s stock after acquiring an additional 90,647 shares during the period. Virtu Financial LLC owned 0.09% of Navidea Biopharmaceuticals worth $26,000 as of its most recent SEC filing.

ILLEGAL ACTIVITY NOTICE: “Navidea Biopharmaceuticals (NAVB) Stock Price Down 16.7%” was reported by Highlight Press and is the property of of Highlight Press. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at

Navidea Biopharmaceuticals Company Profile (NYSEAMERICAN:NAVB)

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment.

Recommended Story: How does a 12b-1 fee affect fund performance?

Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with's FREE daily email newsletter.